Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 34

Results For "framework"

337 News Found

NITI Aayog launches report on best practices in district hospitals
Public Health | October 01, 2021

NITI Aayog launches report on best practices in district hospitals

A total of 707 district hospitals across all states and union territories participated in the performance assessment. The Health Management Information System (HMIS) data for the year 2017–18 has been used as a baseline for this exercise


WHO new Essential Medicines Lists focus on diabetes and cancer
Public Health | September 30, 2021

WHO new Essential Medicines Lists focus on diabetes and cancer

The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all


Machine Learning to understand and prevent disease
Digitisation | September 17, 2021

Machine Learning to understand and prevent disease

Barbara Engelhardt moves her computational and statistics lab to Gladstone


CRAMS to drive growth for Indian pharma industry: report
News | September 06, 2021

CRAMS to drive growth for Indian pharma industry: report

The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion


Biotech-PRIDE guidelines released
Biotech | August 05, 2021

Biotech-PRIDE guidelines released

Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.


Industry-academia collaboration key to strengthening pharma R&D
News | March 04, 2021

Industry-academia collaboration key to strengthening pharma R&D

The next phase of growth in pharma depends on the industry-oriented workforce, risk investment, academic revamp, and creation of R&D hubs, say experts .


Pharma industry bullish on complex generics and biosimilars
News | February 25, 2021

Pharma industry bullish on complex generics and biosimilars

While top industry leaders are optimistic about the growth, they expect the special incentives and regulatory streamlining from the government’s side